Immunovia AB (publ) (IMMNOV.ST)
SEK 0.66
(1.23%)
SEK 0.66
(1.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 291.35 Million SEK | 54.94% |
| 2022 | 188.14 Million SEK | 3.06% |
| 2021 | 182.55 Million SEK | 4.28% |
| 2020 | 175.06 Million SEK | 23.79% |
| 2019 | 141.42 Million SEK | 24.23% |
| 2018 | 113.83 Million SEK | 63.17% |
| 2017 | 69.76 Million SEK | 76.72% |
| 2016 | 39.48 Million SEK | 61.6% |
| 2015 | 24.43 Million SEK | 162.18% |
| 2014 | 9.31 Million SEK | 233.73% |
| 2013 | 2.79 Million SEK | 866.46% |
| 2012 | 288.91 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 24.31 Million SEK | 2.51% |
| 2024 Q2 | 23.99 Million SEK | -1.32% |
| 2023 FY | 291.5 Million SEK | 54.94% |
| 2023 Q2 | 179.99 Million SEK | 270.64% |
| 2023 Q1 | 48.56 Million SEK | -4.25% |
| 2023 Q3 | 39.23 Million SEK | -78.2% |
| 2023 Q4 | 23.71 Million SEK | -39.55% |
| 2022 Q3 | 40.81 Million SEK | -18.87% |
| 2022 FY | 188.14 Million SEK | 3.06% |
| 2022 Q4 | 50.71 Million SEK | 24.25% |
| 2022 Q2 | 50.31 Million SEK | 8.67% |
| 2022 Q1 | 46.29 Million SEK | -8.21% |
| 2021 Q3 | 37.64 Million SEK | -31.01% |
| 2021 Q1 | 39.91 Million SEK | -17.27% |
| 2021 Q2 | 54.56 Million SEK | 36.69% |
| 2021 FY | 182.55 Million SEK | 4.28% |
| 2021 Q4 | 50.43 Million SEK | 33.99% |
| 2020 FY | 175.06 Million SEK | 23.79% |
| 2020 Q1 | 43.39 Million SEK | 14.64% |
| 2020 Q2 | 39.85 Million SEK | -8.17% |
| 2020 Q4 | 48.24 Million SEK | 10.74% |
| 2020 Q3 | 43.56 Million SEK | 9.32% |
| 2019 Q2 | 35.89 Million SEK | 7.94% |
| 2019 Q4 | 37.85 Million SEK | 9.83% |
| 2019 Q1 | 33.25 Million SEK | 6.15% |
| 2019 FY | 141.42 Million SEK | 24.23% |
| 2019 Q3 | 34.46 Million SEK | -3.98% |
| 2018 FY | 113.83 Million SEK | 63.17% |
| 2018 Q4 | 31.32 Million SEK | 29.54% |
| 2018 Q3 | 24.18 Million SEK | -29.49% |
| 2018 Q1 | 24.02 Million SEK | 0.63% |
| 2018 Q2 | 34.3 Million SEK | 42.8% |
| 2017 Q1 | 13.44 Million SEK | 4.21% |
| 2017 FY | 69.76 Million SEK | 76.72% |
| 2017 Q4 | 23.87 Million SEK | 47.52% |
| 2017 Q3 | 16.18 Million SEK | -0.57% |
| 2017 Q2 | 16.27 Million SEK | 21.09% |
| 2016 Q3 | 9.22 Million SEK | -5.19% |
| 2016 Q4 | 12.89 Million SEK | 39.84% |
| 2016 FY | 39.48 Million SEK | 61.6% |
| 2016 Q2 | 9.72 Million SEK | 27.48% |
| 2016 Q1 | 7.63 Million SEK | 211.75% |
| 2015 FY | 24.43 Million SEK | 162.18% |
| 2015 Q4 | 2.44 Million SEK | 0.0% |
| 2015 Q1 | 1.33 Million SEK | 70.83% |
| 2015 Q3 | 2.44 Million SEK | 83.29% |
| 2015 Q2 | 1.33 Million SEK | 0.0% |
| 2014 Q4 | 781.75 Thousand SEK | 0.0% |
| 2014 Q1 | 235.55 Thousand SEK | 0.0% |
| 2014 Q2 | 235.55 Thousand SEK | 0.0% |
| 2014 Q3 | 781.75 Thousand SEK | 231.87% |
| 2014 FY | 9.31 Million SEK | 233.73% |
| 2013 FY | 2.79 Million SEK | 866.46% |
| 2012 FY | 288.91 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AroCell AB (publ) | 57.68 Million SEK | -405.102% |
| Devyser Diagnostics AB (publ) | 204.6 Million SEK | -42.401% |
| Prostatype Genomics AB (publ) | 3.22 Million SEK | -8934.202% |
| SenzaGen AB | 49.67 Million SEK | -486.554% |
| Spermosens AB | 10.72 Million SEK | -2616.578% |